DR. ANGEL K. MARKOV, MD
Osteopathic Medicine at State St, Jackson, MS

5944020, Aug 31, 1999

Oct 3, 1997

8/943836

Angel K. Markov - Jackson MS
Paul J. Marangos - Encinitas CA
Anthony W. Fox - Rancho LaCosta CA

Cypros Pharmaceutical Corp. - Carlsbad CA

A61B 1900

128898

When fructose-1,6-diphosphate (FDP) is used as an inotropic drug in patients who have undergone surgery involving cardiopulmonary bypass, it can increase the pumping strength of a struggling heart, without increasing the heartbeat rate. As such, FDP can reduce the dosages of (and in some some cases eliminate the need for) other inotropic drugs such as dobutamine, epinephrin, or amrinone lactate, which have undesired and potentially dangerous side effects, mainly involving increasing the heartbeat rate, which imposes substantial additional stresses on hearts that are struggling to regain strength after cardiopulmonary bypass surgery.

6312707, Nov 6, 2001

Jun 12, 2000

9/591786

Angel K. Markov - Jackson MS
Anthony W. Fox - Rancho LaCosta CA
Paul J. Marangos - Encinitas CA

Questcor Pharmaceuticals, Inc. - Union City CA

A61F 202

424423

Fructose-1,6-diphosphate (FDP) has been shown, in double-blinded controlled clinical trials on patients with sickle cell anemia, to substantially reduce the pain suffered by such patients during the recurrent ischemic crises that are caused by red blood cell sickling. Tests on patients who have been hospitalized for such crises demonstrated that when they received an intravenous injection of FDP, they reported substantially lower pain levels during their hospital stays than control groups that received identical treatment without any FDP. Apparently, FDP has never previously been used or even tested in human clinical trials, to treat sickle cell anemia. In addition, FDP has never previously been reported to have any analgesic (pain-reducing) activity.

6074658, Jun 13, 2000

Oct 3, 1997

8/943688

Angel K. Markov - Jackson MS
Anthony W. Fox - Rancho LaCosta CA
Paul J. Marangos - Encinitas CA

Cypros Pharmaceutical Corp. - Carlsbad CA

A61F 202

424423

Fructose-1,6-diphosphate (FDP) has been shown, in double-blinded controlled clinical trials on patients with sickle cell anemia, to substantially reduce the pain suffered by such patients during the recurrent ischemic crises that are caused by red blood cell sickling. Tests on patients who have been hospitalized for such crises demonstrated that when they received an intravenous injection of FDP, they reported substantially lower pain levels during their hospital stays than control groups that received identical treatment without any FDP. Apparently, FDP has never previously been used or even tested in human clinical trials, to treat sickle cell anemia. In addition, FDP has never previously been reported to have any analgesic (pain-reducing) activity.

5858985, Jan 12, 1999

Oct 3, 1997

8/943438

Angel K. Markov - Jackson MS

A61K 3170, C07H 1104

514 25

Fructose-1,6-diphosphate (FDP), a sugar-phosphate compound, can be useful in treating asthma, when administered as an inhalable drug, either by itself or as a component of a mixed formulation. On a cellular level, inhalable FDP appears to offer at least four beneficial effects for asthma sufferers: (1) it reduces histamine release by activated mast cells; (2) it suppresses production of oxygen free radicals by polymorphonuclear cells; (3) it helps suppress the activation and proliferation of T-lymphocytes; and, (4) it helps reduce the expression of interleukin compounds by T-lymphocytes. All four effects have been measured and shown to occur in animal and/or human tests, and these effects render FDP likely to help reduce and retard the progressive worsening of asthma that occurs in many sufferers. In addition, when tested in inhalable form on humans, FDP was shown to increase bronchial flow rates. All of these effects are beneficial, and can help asthma patients treated with FDP use asthma-control drugs which impose less stress on the user than more potent, aggressive asthma-control drugs.

4546095, Oct 8, 1985

Sep 3, 1982

6/414551

Angel K. Markov - Jackson MS

A61K 3166, A61K 3170, C12P 1924

514 23

The invention relates to the treatment of heart disorders. Disruption of heart action or occulision of heart artery results in oxygen deprivation and aerobic metabolism ceases. Unless effective treatment is administered acidosis renders anaerobic metabolism inactive and irreversible tissue damage occurs. Fructose-1,6-diphosphate is used as a therapeutic agent for treating mammalian subjects experiencing myocardial infection in order to prevent ischemic tissue from irreversible tissue damage.

4703040, Oct 27, 1987

Oct 8, 1985

6/785778

Angel K. Markov - Jackson MS

C07H 1104, A61K 910, A61K 3166

514 23

Fructose-1,6-diphosphate is administered intravenously to a mammalian subject experiencing adult respiratory distress syndrome (ARDS) in an amount sufficient to inhibit pulmonary microvascular damage.

5039665, Aug 13, 1991

Aug 29, 1990

7/576154

Angel K. Markov - Jackson MS

A61K 3166, A61K 3170

514 23

The invention relates to methods of treatment of patients with heat disorders using fructose-1,6-diphosphate.

4757052, Jul 12, 1988

Oct 4, 1985

6/784381

Angel K. Markov - Jackson MS

A61K 3166, A61K 3170, C12P 1924

514 23

The invention relates to methods of treatment of patients with heart disorders and methods of preserving stored blood using fructose-1,6-diphosphate.